GPM Announces Investigation of Amicus Therapeutics, Inc.
October 09 2015 - 9:40PM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces that it is
investigating potential claims on behalf of investors of Amicus
Therapeutics, Inc. (“Amicus” or the “Company”) (NASDAQ: FOLD)
concerning the Company’s and its officers’ possible violations of
federal securities laws in connection with the Company’s recently
announced delay in submitting a New Drug Application (“NDA”) to the
Food and Drug Administration (“FDA”).
On October 2, 2015, the Company disclosed that the FDA had
“requested further integration of existing clinical data across
studies” in connection with Amicus’s migalastat monotherapy
treatment for Fabry disease, and that, “Amicus does not anticipate
being in a position to submit the NDA for migalastat monotherapy
in the United States by the end of this year.” On this
news, the Company’s stock fell $7.36, or over 53%, to close at
$6.39 on October 2, 2015, thereby injuring Amicus investors. News
of the delay in the FDA approval process comes shortly after the
Company completed an offering of securities to the public.
If you purchased Amicus securities, have information or would
like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire,
of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California
90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to
shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151009006002/en/
Glancy Prongay & Murray LLP, Los AngelesLesley Portnoy,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Apr 2024 to May 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From May 2023 to May 2024